A broad-spectrum neutralizing antibody w328-6a1 against coronavirus and applications thereof

Abstract

The application discloses a broad-spectrum neutralizing antibody W328-6A1 against coronavirus and application thereof. The application provides an IgG antibody, named W328-6A1 antibody, which is composed of a light chain and a heavy chain; CDR1, CDR2 and CDR3 in a heavy chain variable region in the heavy chain are sequentially shown in the 45th-52nd, 70th-76th and 115th-137th positions of SEQ ID NO:1; CDR1, CDR2 and CDR3 in a light chain variable region in the light chain are sequentially shown in the 45th-53rd, 71st-73rd and 110th-121st positions of SEQ ID NO:3. The W328-6A1 antibody not only has the effect of neutralizing atypical pneumonia virus, but also has broad-spectrum neutralizing activity on other coronaviruses. The application has great application value for prevention and control of beta genus coronavirus and will have far-reaching social significance.

Description

Technical Field

[0001] This invention belongs to the field of biotechnology and relates to a broad-spectrum neutralizing antibody W328-6A1 against coronaviruses and its applications. Background Technology

[0002] Severe Acute Respiratory Syndrome (SARS-CoV-1) is a type of beta coronavirus that is transmitted through the respiratory tract. SARS-CoV infection is characterized by rapid onset, rapid spread, and high mortality. The main symptoms include hypoxia, cyanosis, and high fever. It often progresses to severe infection, leading to rapid breathing or acute respiratory distress syndrome, accompanied by septic shock, metabolic acidosis, coagulation disorders, and multiple organ failure.

[0003] Beta coronaviruses share extensive conserved regions in terms of sequence and structure. Developing preventative and therapeutic technologies for SARS-CoV strains is of great value and significance in responding to potential emerging coronavirus infectious diseases in the future.

[0004] Monoclonal antibodies can be mass-produced industrially. Their high affinity and specificity for binding to antigens significantly reduce adverse reactions in clinical applications. Furthermore, antibody molecules can be modified to increase their antiviral efficacy. Due to their specificity and flexibility of use, antibodies are a very promising tool in the treatment of infectious diseases. Stockpiling antibody sequences against SARS virus can provide effective prevention and treatment measures in the immediate event of a potential new coronavirus outbreak. Summary of the Invention

[0005] The purpose of this invention is to provide a broad-spectrum neutralizing antibody W328-6A1 against coronaviruses and its applications.

[0006] This invention provides an IgG antibody, named W328-6A1 antibody, composed of a light chain and a heavy chain; the CDR1, CDR2, and CDR3 in the variable region of the heavy chain are shown as positions 45-52, 70-76, and 115-137 in SEQ ID NO: 1, respectively; the CDR1, CDR2, and CDR3 in the variable region of the light chain are shown as positions 45-53, 71-73, and 110-121 in SEQ ID NO: 3, respectively.

[0007] Specifically, the heavy chain variable region is shown in positions 20-148 of SEQ ID NO: 1.

[0008] Specifically, the variable region of the light chain is shown in positions 20-131 of SEQ ID NO: 3.

[0009] Specifically, the heavy chain is either (a) or (b) as follows: (a) the protein represented by positions 20-478 of SEQ ID NO: 1; (b) the protein represented by SEQ ID NO: 1;

[0010] Specifically, the light chain is either (c) or (d) as follows: (c) the protein shown in positions 20-237 of SEQ ID NO: 3; (d) the protein shown in SEQ ID NO: 3.

[0011] The gene encoding the IgG antibody is also within the scope of protection of this invention.

[0012] Specifically, the gene encoding the heavy chain is as follows (1) or (2):

[0013] (1) The DNA molecule represented by nucleotides 58-1437 in SEQ ID NO: 2;

[0014] (2) The DNA molecule shown in SEQ ID NO: 2.

[0015] Specifically, the gene encoding the light chain is as follows (3) or (4):

[0016] (3) The DNA molecule represented by nucleotides 58-714 in SEQ ID NO: 4;

[0017] (4) The DNA molecule shown in SEQ ID NO: 4.

[0018] This invention also protects the use of any of the above-described IgG antibodies in the preparation of products.

[0019] This invention also protects a product whose active ingredient is any of the IgG antibodies described above.

[0020] The product is one of the following (e), (f), (g), or (h):

[0021] (e) Vaccines against the coronavirus;

[0022] (f) Medicines used to prevent and / or treat coronavirus infection;

[0023] (g) Virus inhibitors targeting coronaviruses;

[0024] (h) Preparations used to neutralize coronaviruses.

[0025] The preparation is a vaccine preparation or a pharmaceutical preparation.

[0026] Specifically, the coronavirus in question is a beta coronavirus.

[0027] Specifically, the coronaviruses mentioned are SARS virus, novel coronavirus, bat coronavirus, or pangolin coronavirus.

[0028] Specifically, the novel coronavirus is any of the following strains: wild-type novel coronavirus, novel coronavirus Alpha strain, novel coronavirus Beta strain, novel coronavirus Gamma strain, novel coronavirus Delta strain, novel coronavirus Omeprone BA.1 strain, novel coronavirus Omeprone BA.2 strain, novel coronavirus Omeprone BA.4 / 5 strain, novel coronavirus Omeprone BF.7 strain, novel coronavirus Omeprone BQ.1 strain, novel coronavirus Omeprone BQ.1.1 strain, novel coronavirus Omeprone XBB strain, novel coronavirus Omeprone XBB.1 strain, or novel coronavirus Omeprone XBB.1.5 strain.

[0029] Specifically, the bat coronavirus is either the bat coronavirus WIV16 strain or the bat coronavirus RaTG13 strain.

[0030] Specifically, the pangolin coronavirus is either the pangolin coronavirus GD strain or the pangolin coronavirus P4L strain.

[0031] This invention screens memory B cells generated from antibody-producing peripheral blood mononuclear cells of patients infected with SARS-CoV-2, obtaining a monoclonal antibody that specifically binds to the spike protein, named W328-6A1 antibody. The W328-6A1 antibody provided by this invention not only neutralizes SARS-CoV-2 but also exhibits broad-spectrum neutralizing activity against other coronaviruses. This invention has significant application value for the prevention and control of β-coronaviruses and will have profound social implications. Attached Figure Description

[0032] Figure 1 The neutralizing activity of W328-6A1 antibody against atypical pneumonia virus pseudoviruses was measured.

[0033] Figure 2 The W328-6A1 antibody exhibits broad-spectrum neutralizing activity against various coronavirus pseudoviruses. Detailed Implementation

[0034] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.

[0035] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available. Unless otherwise specified, all quantitative experiments in the following examples were performed in triplicate, and the results were averaged. 293F cells and 293T cells were commercially available human embryonic kidney epithelial cells. The pMD18-T vector was a commercially available plasmid vector. The pcDNA3.1(+) vector was from Invitrogen, catalog number V790-20.

[0036] hACE2-hela cells (i.e. "HeLa cell lines stably expressing the ACE2molecules"), recorded in the following literature: Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen ,P.,Liao,H.,Feng,Y.,Li,X.,Shi,X.,Zhang,Z.,Zhang,F.,Ding,Q.,Zhang,T.,Wang,X.&Zhang,L.Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity 54, 1611-1621.e1615, doi:10.1016 / j.immuni.2021.06.003(2021).

[0037] Example 1: Discovery and preparation of W328-6A1 antibody

[0038] Memory B cells were isolated from peripheral blood mononuclear cells of patients recovering from SARS-CoV-1 infection and disease, and the antibody gene of the memory B cells was amplified to obtain the antibody sequence. Through extensive comparison, analysis, preparation, and efficacy verification, the inventors of this invention discovered a new SARS-CoV-1 IgG antibody with excellent activity, which was named W328-6A1 antibody.

[0039] The full-length heavy chain amino acid sequence of the W328-6A1 antibody is shown in SEQ ID NO: 1. In SEQ ID NO: 1, amino acid residues 1-19 form the signal peptide (guiding the protein to be secreted extracellularly), amino acid residues 20-148 form the variable region of the heavy chain, and amino acid residues 149-478 form the constant region of the heavy chain. CDR1, CDR2, and CDR3 in the variable region of the heavy chain are shown as follows: positions 45-52 (GFTVSNNY), ​​positions 70-76 (IYTGGSS), and positions 115-137 (TRDRHYYDFLTGRAKGADWYSDL) in SEQ ID NO: 1, respectively.

[0040] The full-length light chain amino acid sequence of the W328-6A1 antibody is shown in SEQ ID NO: 3. In SEQ ID NO: 3, amino acid residues 1-19 constitute the signal peptide (guiding the protein to be secreted extracellularly), amino acid residues 20-131 constitute the variable region of the light chain, and amino acid residues 132-237 constitute the constant region of the light chain. CDR1, CDR2, and CDR3 in the variable region of the light chain are shown as positions 45-53 (SSNIGAGHD), 71-73 (TDT), and 110-121 (QSSDSSLSGSKV) in SEQ ID NO: 3, respectively.

[0041] Example 2: Preparation of W328-6A1 antibody

[0042] I. Construction of Recombinant Plasmids

[0043] The heavy chain DNA molecule was inserted into the pMD18-T vector to obtain the heavy chain expression vector. The heavy chain DNA molecule consists of the following three elements from upstream to downstream: the promoter shown in SEQ ID NO: 5, the full-length heavy chain coding gene shown in SEQ ID NO: 2, and the terminator shown in SEQ ID NO: 6.

[0044] The light chain DNA molecule was inserted into the pMD18-T vector to obtain the light chain expression vector. The light chain DNA molecule consists of the following three elements from upstream to downstream: the promoter shown in SEQ ID NO: 5, the full-length light chain coding gene shown in SEQ ID NO: 4, and the terminator shown in SEQ ID NO: 6.

[0045] Both heavy chain DNA molecules and light chain DNA molecules are double-stranded DNA molecules.

[0046] II. Construction of Recombinant Cells

[0047] The heavy chain expression vector and the light chain expression vector were co-transfected into 293F cells to obtain recombinant cells.

[0048] III. Antibody Preparation

[0049] 1. Take the recombinant cells obtained in step 2 and culture them in DMEM medium containing 2% fetal bovine serum for 72 h. Then centrifuge at 4℃ and 4000 rpm for 30 min, collect the supernatant and filter it through a 0.45 μm filter membrane.

[0050] 2. Affinity chromatography

[0051] Affinity chromatography packing material: Protein A Resin (Genscript Biotechnology, product catalog number L00210);

[0052] Operating steps: ① Mix 300 mL of the filtrate obtained in step 1 with 3 mL of affinity chromatography packing material and incubate at 4 °C for 16 h; ② Add the mixture to a 25 mL gravity flow empty column to trap the packing material; ③ Wash the column with 60 mL of binding buffer; elute the target protein with 30 mL of elution buffer, collect the post-column solution, and adjust the pH to neutral.

[0053] Binding buffer: Dissolve 112.6g of glycine and 175.2g of sodium chloride in water and bring the volume to 1L. Adjust the pH to 8.0 with sodium hydroxide.

[0054] Elution buffer: Dissolve 7.5g of glycine in water and bring the volume to 500ml. Adjust the pH to 3.0 with hydrochloric acid.

[0055] 3. Take the post-column solution obtained in step 2, concentrate it with an ultrafiltration concentrator and replace the system with PBS buffer (pH 7.2, 10mM) to obtain W328-6A1 antibody solution.

[0056] Example 3: Neutralizing activity of W328-6A1 antibody against SARS-CoV-1

[0057] I. Preparation of SARS-CoV-1 pseudovirus

[0058] Co-transfection of 293T cells with a plasmid expressing the SARS-CoV-1 membrane protein and the backbone plasmid pNL4-3R-E-luciferase yielded an infectious but non-replicating SARS-CoV-1 pseudovirus, with infectivity similar to live SARS-CoV-1 virus. The backbone plasmid pNL4-3R-E-luciferase, i.e., the backbone plasmid pNL4-3R-E containing luciferase (i.e., vector with the luciferase gene containing backbone pNL4-3R-E in the literature), is described in the following literature: Wang Q, Liu L, Ren W, Gettie A, Wang H, Liang Q, Shi X, Montefiori DC, Zhou T, Zhang L. Cell Rep. 2019.

[0059] The gene encoding the SARS-CoV-1 membrane protein was inserted between the BamHII and EcoRI restriction sites of the pcDNA3.1(+) vector to obtain a plasmid expressing the SARS-CoV-1 membrane protein. The plasmid expressing the SARS-CoV-1 membrane protein and the backbone plasmid pNL4-3R-E-luciferase were co-transfected into 293T cells and incubated at 37°C in DMEM medium containing 10% fetal bovine serum. The cell culture supernatant was collected 60 hours after transfection; this was the viral fluid containing SARS-CoV-1 pseudovirus, referred to as SARS-CoV-1 viral fluid. The SARS-CoV-1 membrane protein is shown in SEQ ID NO: 7. The gene encoding the SARS-CoV-1 membrane protein is shown in SEQ ID NO: 8 (the codon-optimized sequence).

[0060] II. Detection of antibody neutralizing activity

[0061] Test virus solution: SARS-CoV-1 virus solution prepared in step one.

[0062] 1. Take the W328-6A1 antibody solution prepared in Example 2 and perform serial dilution with PBS buffer (pH 7.2, 10mM) to obtain antibody dilutions of various concentrations.

[0063] 2. Take a 96-well cell culture plate and add 100 μl of antibody diluent and 50 μl of test virus solution to each well (the virus concentration in 50 μL of test virus solution is 1×10⁻⁶). 4Incubate at 37°C for 1 hour using TCID50 / ml. Use an equal volume of PBS buffer (pH 7.2, 10mM) instead of the antibody dilution solution as a virus control. Use an equal volume of DMEM medium containing 10% fetal bovine serum instead of the test virus solution as a cell control.

[0064] 3. After completing step 2, take the cell culture plate and seed each well with 100 μl of hACE2-hela cell suspension (the solvent used to prepare the cell suspension is DMEM medium containing 10% fetal bovine serum, and the concentration of hACE2-hela cells in the cell suspension is 2 × 10⁻⁶). 5 (cells / ml), incubated at 37°C for 64 hours.

[0065] 4. After completing step 3, take the cell culture plate, discard the supernatant, add 150 μl of lysis buffer (Microglass Biotechnology, catalog number T003, follow the instructions) to each well, and incubate at 37°C for 5 minutes.

[0066] 5. After completing step 4, take the cell culture plate and detect the luciferase activity.

[0067] Each process is configured with multiple duplicate holes.

[0068] Neutralization activity (%) = [1 - (fluorescence intensity of experimental group - fluorescence intensity of cell control) / (fluorescence intensity of virus control - fluorescence intensity of cell control)] × 100%.

[0069] Neutralization activity results are shown in Figure 1 . Figure 1 The vertical axis represents neutralizing activity (%), and the horizontal axis represents the antibody concentration (μg / ml) logarithm to base 10. The antibody concentration refers to the antibody concentration in the mixed system consisting of 100 μl of antibody dilution and 50 μl of test virus solution in step 2.

[0070] The antibody concentration at which the neutralizing activity is 50% was calculated using Prism 8 software, i.e., the IC50 value of the antibody.

[0071] The IC50 value of the W328-6A1 antibody against SARS-CoV-1 pseudovirus was 303.35 ng / ml.

[0072] Example 4: Broad-spectrum neutralizing activity of W328-6A1 antibody against coronaviruses

[0073] I. Preparation of Coronavirus Pseudoviruses

[0074] The gene encoding the coronavirus membrane protein was inserted between the BamHII and EcoRI restriction sites of the pcDNA3.1(+) vector to obtain a plasmid expressing the coronavirus membrane protein. The plasmid expressing the coronavirus membrane protein and the backbone plasmid pNL4-3R-E-luciferase were co-transfected into 293T cells and incubated at 37°C (using DMEM medium containing 10% fetal bovine serum). The cell culture supernatant was collected 60 hours after transfection; this was the viral solution containing coronavirus pseudoviruses.

[0075] Viral solutions of pseudoviruses from 18 coronavirus strains were prepared, specifically pseudoviruses of 14 novel coronavirus strains, 2 bat coronavirus strains, and 2 pangolin coronavirus strains. The 14 novel coronavirus strains refer to the following strains: wild-type novel coronavirus, novel coronavirus Alpha strain, novel coronavirus Beta strain, novel coronavirus Gamma strain, novel coronavirus Delta strain, novel coronavirus Omeprone BA.1 strain, novel coronavirus Omeprone BA.2 strain, novel coronavirus Omeprone BA.4 / 5 strain, novel coronavirus Omeprone BF.7 strain, novel coronavirus Omeprone BQ.1 strain, novel coronavirus Omeprone BQ.1.1 strain, novel coronavirus Omeprone XBB strain, novel coronavirus Omeprone XBB.1 strain, and novel coronavirus Omeprone XBB.1.5 strain. The 2 bat coronavirus strains refer to bat coronavirus WIV16 and bat coronavirus RaTG13. The two pangolin coronavirus strains refer to the pangolin coronavirus GD strain and the pangolin coronavirus P4L strain. The membrane proteins of each coronavirus and their coding genes are shown in Table 1.

[0076] Table 1

[0077]

[0078]

[0079] II. Detection of antibody neutralizing activity

[0080] Test virus solutions: virus solutions of 18 coronavirus strains prepared in step one.

[0081] The method is the same as step two of Example 3.

[0082] Neutralization activity results are shown in Figure 2 . Figure 2The vertical axis represents neutralizing activity (%), and the horizontal axis represents the antibody concentration (μg / ml) logarithm to base 10. The antibody concentration refers to the antibody concentration in the mixed system consisting of 100 μL of antibody diluent and 50 μL of test virus solution in step 2.

[0083] The IC50 values ​​of the W328-6A1 antibody against each strain are shown in Table 2.

[0084] Table 2

[0085] IC50 value (μg / ml) Wild-type novel coronavirus (WT) 0.407347 Novel Coronavirus Alpha Strain 0.896812 Novel Coronavirus Beta Strain 0.619793 Novel Coronavirus Gamma Strain 0.557978 novel coronavirus Delta strain 0.416765 Novel coronavirus Omeprone BA.1 strain 0.402262 Novel coronavirus Omeprone BA.2 strain 1.11949 Novel coronavirus Omeprone BA.4 / 5 strain 4.256879 Novel coronavirus Omeprone BF.7 strain 4.944503 Novel coronavirus Omeprone BQ.1 strain 5.830537 Novel coronavirus Omeprone BQ.1.1 strain 9.052037 Novel coronavirus Omeprone XBB strain 7.573986 Novel coronavirus Omeprone XBB.1 strain 16.95978 Novel coronavirus Omeprone XBB.1.5 strain 26.15618 bat coronavirus WIV16 strain 0.08148 bat coronavirus RaTG13 strain 0.019655 Pangolin coronavirus GD strain 0.085006 Pangolin coronavirus P4L strain 0.069957

[0086] The present invention has been described in detail above. For those skilled in the art, the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. Although specific embodiments have been given, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein. Some of the essential features can be applied within the scope of the following appended claims.

Claims

1. An IgG antibody that binds to the SARS-CoV-1 spike protein, comprising a light chain and a heavy chain; wherein CDR1, CDR2, and CDR3 in the variable region of the heavy chain are as shown in positions 45-52, 70-76, and 115-137 of SEQ ID NO: 1, respectively; and wherein CDR1, CDR2, and CDR3 in the variable region of the light chain are as shown in positions 45-53, 71-73, and 110-121 of SEQ ID NO: 3, respectively.

2. The IgG antibody as described in claim 1, characterized in that: The heavy chain variable region is shown in bits 20-148 of SEQ ID NO: 1; The variable region of the light chain is shown in positions 20-131 of SEQ ID NO:

3.

3. The IgG antibody as described in claim 2, characterized in that: The heavy chain is either (a) or (b) the protein shown in positions 20-478 of SEQ ID NO: 1; or (b) the protein shown in SEQ ID NO:

1. The light chain is either (c) or (d) as follows: (c) the protein shown at positions 20-237 of SEQ ID NO: 3; (d) the protein shown in SEQ ID NO:

3.

4. A gene encoding the IgG antibody of any one of claims 1 to 3.

5. The use of the IgG antibody according to claim 1, 2, or 3 in the preparation of the product; The product is one of the following (f), (g), or (h): (f) Medicines used to prevent and / or treat coronavirus infection; (g) Virus inhibitors targeting coronaviruses; (h) Preparations used to neutralize coronaviruses; The coronaviruses mentioned are: wild-type novel coronavirus, novel coronavirus Alpha strain, novel coronavirus Beta strain, novel coronavirus Gamma strain, novel coronavirus Delta strain, novel coronavirus Omeprone BA.1 strain, novel coronavirus Omeprone BA.2 strain, novel coronavirus Omeprone BA.4 / 5 strain, novel coronavirus Omeprone BF.7 strain, novel coronavirus Omeprone BQ.1 strain, novel coronavirus Omeprone BQ.1.1 strain, novel coronavirus Omeprone XBB strain, bat coronavirus WIV16 strain, bat coronavirus RaTG13 strain, pangolin coronavirus GD strain, or pangolin coronavirus P4L strain.

6. A product wherein the active ingredient is the IgG antibody as described in claim 1, 2, or 3; The product is one of the following (f), (g), or (h): (f) Medicines used to prevent and / or treat coronavirus infection; (g) Virus inhibitors targeting coronaviruses; (h) Preparations used to neutralize coronaviruses; The coronaviruses mentioned are: wild-type novel coronavirus, novel coronavirus Alpha strain, novel coronavirus Beta strain, novel coronavirus Gamma strain, novel coronavirus Delta strain, novel coronavirus Omeprone BA.1 strain, novel coronavirus Omeprone BA.2 strain, novel coronavirus Omeprone BA.4 / 5 strain, novel coronavirus Omeprone BF.7 strain, novel coronavirus Omeprone BQ.1 strain, novel coronavirus Omeprone BQ.1.1 strain, novel coronavirus Omeprone XBB strain, bat coronavirus WIV16 strain, bat coronavirus RaTG13 strain, pangolin coronavirus GD strain, or pangolin coronavirus P4L strain.

Images